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Abstract: The concept that disease rooted principally in 
chronic aberrant constitutive and reactive activation of 
mast cells (MCs), without the gross MC neoplasia in mas-
tocytosis, first emerged in the 1980s, but only in the last 
decade has recognition of “mast cell activation syndrome” 
(MCAS) grown significantly. Two principal proposals for 
diagnostic criteria have emerged. One, originally pub-
lished in 2012, is labeled by its authors as a “consensus” 
(re-termed here as “consensus-1”). Another sizable con-
tingent of investigators and practitioners favor a differ-
ent approach (originally published in 2011, newly termed 
here as “consensus-2”), resembling “consensus-1” in 
some respects but differing in others, leading to substan-
tial differences between these proposals in the numbers 
of patients qualifying for diagnosis (and thus treatment). 
Overdiagnosis by “consensus-2” criteria has potential to 
be problematic, but underdiagnosis by “consensus-1” 
criteria seems the far larger problem given (1) increas-
ing appreciation that MCAS is prevalent (up to 17% of the 
general population), and (2) most MCAS patients, regard-
less of illness duration prior to diagnosis, can eventually 
identify treatment yielding sustained improvement. We 
analyze these proposals (and others) and suggest that, 
until careful research provides more definitive answers, 
diagnosis by either proposal is valid, reasonable, and 
helpful.
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Introduction
The concept that a class of diseases rooted principally just 
in chronic aberrant constitutive and/or reactive activa-
tion of mast cells (MCs; and with only modest increases 
in MC numbers due to reduced apoptosis rather than the 
marked MC neoplasia defining the rare disorder of mas-
tocytosis) ought to exist was first published in 1984–1991 
[1–3]. The heterogeneity of the full range of such patients’ 
clinical presentations is extreme, but symptoms/find-
ings (typically waxing/waning and migratory) often 
include flushing, allergic-type issues, fatigue, dermato-
graphism, cognitive dysfunction, irritated eyes/nose/
mouth/throat, adenitis, dyspnea, palpitations, nausea, 
reflux, abdominal pain, diarrhea (often alternating with 
constipation), interstitial cystitis, vulvovaginitis, men-
orrhagia, dysmenorrhea, fibromyalgia-type pain, joint 
hypermobility, benign growth anomalies (e.g. cysts, fibro-
sis, vascular anomalies, poor healing), headache, sensory 
neuropathy, dysautonomias (e.g. orthostatic hypotension, 
blood pressure and heart rate lability, thermal dysregula-
tion), anxiety and mood disorders, and an assortment of 
metabolic/endocrinologic (e.g. thyroid) aberrancies. In 
2007, the first case reports were published [4, 5], followed 
shortly by a limited proposal for diagnostic criteria in cases 
where MC clonality could be identified [6]. Subsequent 
literature regarding this newly recognized (but of course 
not truly new) “mast cell activation syndrome” (MCAS) 
included case reports as well as formal studies (mostly 
relatively small scale), reviews, and various proposals for 
formal diagnostic criteria. Two principal such proposals 
emerged – the first published initially in late 2010 [7] and 
the second published initially in early 2011 [8]. The former 
proposal was adjusted by its authors and others and re-
published in 2012 [9], labeled by them at that time as a 
“consensus.” However, followers of MCAS literature know 
there is another sizable world-wide contingent of investi-
gators and practitioners – and patients – who feel there 
are significant problems with the “consensus” approach 
and who thus favor the alternative approach advocated by 
the authors of the 2011 paper, which resembles the “con-
sensus” approach in some respects but differs in a number 
of other respects. An important difference between these 
Mindy S. Marantz: Healthwell Physical Therapy Group, San 
Francisco, CA, USA, Email: mmarantz@healthwellpt.com
Andrew J. Maxwell: Heart of the Valley Pediatric Cardiology, 
Pleasanton, CA, USA, Email: amaxwell@heartofthevalley.us
Kelly K. McCann: The Spring Center, Costa Mesa, CA, USA,  
Email: kellybird28@gmail.com
Dwight L. McKee: Integrative Cancer Consulting, Aptos, CA, USA, 
Email: dlmckeemd@gmail.com
Laurie Menk Otto: Helfgott Research Institute, National College  
of Natural Medicine, Portland, OR, USA,  
Email: laur.menk.otto@gmail.com
Laura A. Pace: Division of Gastroenterology, Hepatology and 
Nutrition, University of Utah, Salt Lake City, UT, USA,  
Email: laura.pace@hsc.utah.edu
Dahra D. Perkins: Elevate Health, Portland, OR, USA,  
Email: dahra.perkins@gmail.com
Laurie Radovsky: St. Paul, MN, USA, Email: laurie@drradovsky.com
Mary S. Raleigh: Restoration Healthcare, Irvine, CA, USA,  
Email: sunnyraleigh@rhealthc.com
Sonia A. Rapaport: Haven Medical, Chapel Hill, NC, USA,  
Email: soniarapnc@gmail.com
Emma J. Reinhold: Royal College of General Practitioners, London, 
UK, Email: e.reinhold@doctors.org.uk
Mark L. Renneker and Aaron M. Roland: Department of Family 
Medicine, University of California San Francisco, San Francisco, 
CA, USA, Email: mark.renneker@ucsf.edu (M.L. Renneker); 
doctoraaron@pacbell.net (A.M. Roland)
William A. Robinson: Division of Hematology/Oncology, University of 
Colorado, Denver, CO, USA, Email: william.robinson@ucdenver.edu
E. Scott Rosenbloom: Sacramento, CA, USA,  
Email: skiprosenbloom@gmail.com
Peter C. Rowe: Department of Pediatrics, Johns Hopkins University, 
Baltimore, MD, USA, Email: prowe@jhmi.edu
Ilene S. Ruhoy: Center for Healing Neurology, Seattle, WA, USA, 
Email: ilene@centerforhealingneurology.com
David S. Saperstein: Center for Complex Neurology, EDS and 
POTS, Phoenix, AZ, USA,  
Email: drsaperstein@complexneurology.com
David A. Schlosser: Patient Navigator, LLC, Reston, VA, USA,  
Email: dschlosser@patientnavigator.com
Jill R. Schofield: Department of Internal Medicine, University of 
Colorado School of Medicine, Aurora, CO, USA,  
Email: js@centerformultisystemdisease.com
Janet E. Settle: Department of Psychiatry, University of Colorado, 
Denver, CO, USA, Email: drjanetsettle@gmail.com
Leonard B. Weinstock: Department of Medicine, Washington 
University, St. Louis, MO, USA, Email: lw@gidoctor.net
Martina Wengenroth: Institute of Neuroradiology, University 
Hospital Lübeck, Lübeck, Germany,  
Email: martina.wengenroth@googlemail.com
Mark Westaway: Westaway Medical, Brisbane, Queensland, 
Australia, Email: drmarkwestaway@gmail.com
Shijun Cindy Xi: Section of Allergy and Immunology, Keck School of 
Medicine, University of Southern California, Los Angeles, CA, USA, 
Email: xicindy@gmail.com
Gerhard J. Molderings: Institute of Human Genetics,  
University Hospital of Bonn, Bonn, Germany, Email: molderings@
uni-bonn.de
138 Afrin et al.: Diagnosis of mast cell activation syndrome
proposals is the number of patients who would qualify for 
an MCAS diagnosis. Underdiagnosis by inappropriately 
restrictive criteria is dangerous given (1) increasing evi-
dence of substantial prevalence of MCAS (various publi-
cations, based on varying amounts of data, have provided 
estimates ranging from “rare” [10] to as high as 17% of the 
general population [11], the latter perhaps unsurprising 
given the increasingly recognized great prevalence of a 
wide range of allergic and inflammatory disorders which 
may be rooted at least partly in MCAS), and (2) experience 
to date (e.g. [12]) suggesting that most MCAS patients, 
regardless of the (typically decades long) duration of 
their complex multisystem unwellness prior to diagnosis, 
eventually identify some regimen which helps them gain 
significant, largely sustainable improvement. Overdiag-
nosis, however, also could be problematic. Furthermore, 
the very recent recognition of “hereditary alpha-trypta-
semia” [HAT, a prevalent condition featuring (1) redun-
dancy of the TPSAB1 gene expressing alpha-tryptase and 
(2) many of the same clinical features as MCAS] is another 
confounder in the challenges facing the diagnostician 
considering MCAS. Given that the original proposals for 
both of the principal schools of MCAS diagnostic thought 
were first published nearly a decade ago and that multi-
ple updates of each have been published since, we feel 
that review, and a frank discussion of the pros and cons, 
of the two proposals, as well as how HAT now “fits in” to 
diagnostic considerations of MCAS, would be helpful. We 
follow this analysis with our recommendations for steps 
forward in research and in practice.
Before diving into this analysis, though, a brief over-
view of what MCAS is – or at least what it is thought by 
most to be – may be helpful. The different “schools of 
thought” proposing different diagnostic criteria have dif-
ferent senses of what the entity of MCAS encompasses, 
and these different senses drive the differences in diag-
nostic criteria. However, there is much about MCAS which 
is uncontested. It is helpful to understand these areas first.
Prior to the introduction of the term “mast cell acti-
vation disease” (MCAD) [7], “mast cell disease” was the 
moniker usually used to refer to the full spectrum of dis-
eases of the MC, which consisted principally of assorted 
forms of the rare disease of mastocytosis and assorted 
allergic diseases of varying prevalence ranging from rare 
(e.g. certain urticarias) to common (e.g. environmental and 
food allergies). That the allergic illnesses very commonly 
reflect aberrant MC activation (MCA) was a background 
biological fact largely lost from conscious consideration in 
everyday practice. Also often lost was the consideration as 
to what manifestations of MCA other than “allergic-type” 
phenomena might also be present in allergy patients. 
These patients often experience “non-allergic” problems 
(commonly inflammatory, sometimes even dystrophic) 
(see Table 1) potentially rooted in chronic aberrant MCA 
but which are left to be addressed by non-allergists even 
less likely to recognize those problems as rooted in MCA. 
Thus, the only “MC disease” recognized by most health 
professionals until recently was the range of (prevalent) 
overtly allergic-type phenomena and (rare) mastocytosis.
In the last 10–15 years, though, it has become appar-
ent that most of the clinical problems in patients with any 
form of “MC disease” – even mastocytosis – are rooted in 
the aberrant activation of the abnormal MCs (i.e. aberrant 
MC mediator production/release), thus leading to the des-
ignation of the new term of MCAD to describe the full spec-
trum of MC diseases, constantly reminding all clinicians of 
the critical issue of aberrant MC activation in these patients. 
Because it also became apparent that some MCAD patients 
did not have either mastocytosis or merely the various 
defined allergic-type phenomena but in fact a wide range 
of clinical consequences of MCA, the term “mast cell activa-
tion syndrome” was coined to refer broadly to this entity [7].
Table 1 lists symptoms/problems which various MCAS 
patients commonly exhibit consequent (directly or indi-
rectly) to chronic aberrant MC mediator expression. Other 
elements, too, though, are needed to make a clear diag-
nosis of MCAS, and disputes have arisen regarding these 
elements. For one, laboratory evidence of MCA is highly 
desirable. However, even if one sets aside arguments about 
which laboratory criteria should be deemed supportive of 
an MCAS diagnosis, mere acquisition of laboratory evi-
dence is problematic for much of the world’s population 
without access to these tests. As such, consideration needs 
to be given to methods of diagnosing MCAS in situations 
where testing is unobtainable, but disputes have led to dif-
ferences in diagnostic criteria proposals, thus challenging 
diagnosticians. Other areas of dispute were therapeutic in 
nature, namely, the validity of, and approach to, (1) treat-
ing patients who have not yet acquired laboratory evidence 
and (2) incorporating treatment results into diagnostic cri-
teria. Given that impact potentially extends to millions of 
patients (if the higher estimates of prevalence are closer to 
the truth), we feel these differences warrant detailed anal-
ysis and open discussion.
We focus this paper on (1) rare patients with primary 
(i.e. clonal) MCAS proven by the presently very limited 
range of laboratory testing routinely available for proving 
such [KIT-D816X mutational analysis, and flow cytom-
etry seeking co-expression on the surfaces of MCs of 
CD117 (the extracellular domain of transmembrane tyros-
ine kinase KIT, the dominant MC regulatory element) 
together with CD25 (the alpha chain of the interleukin-2 
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Table 1: Common symptoms and findings in MCAD.
System   Potential manifestations of MCAD
Constitutional   Fatigue, subjective or objective hyperthermia and/or hypothermia, sweats, flushing, plethora or pallor, 




  Dermatographism, rashes/lesions of many sorts (migratory patchy macular erythema, telangiectasias, 
angiomata, xerosis, striae, warts, tags, folliculitis, ulcers, dyshydrotic eczema), angioedema, alopecia, 
onychodystrophy (e.g. brittle and/or longitudinally ridged nails)
Ophthalmologic   Irritated (often “dry”) eyes, episodic difficulty focusing, lid tremor/tic (blepharospasm)




  Pain or irritation (sometimes “burning”), leukoplakia, ulcers, angioedema, dysgeusia, dental and/or periodontal 
inflammation/decay despite good personal and professional attention to dental hygiene
Lymphatic   Adenopathy (usually sub-pathologic and spontaneously waxing/waning in size, often migratory), adenitis, 
splenitis (typically only modest)
Pulmonary   Airway inflammation at any or all levels, cough, dyspnea (usually mild, episodic, “just can’t catch a deep breath” 
despite normal pulmonary function tests), wheezing (usually quite mild), obstructive sleep apnea regardless of 
weight
Cardiovascular   Presyncope [co-diagnosis of postural orthostatic tachycardia syndrome (POTS) is common; full syncope 
is relatively rare], hypertension, blood pressure lability, palpitations (usually not correlating with 
electrocardiographic events), migratory edema, chest pain (usually non-anginal), atherosclerosis, odd heart 
failure (e.g. takotsubo), allergic angina (Kounis syndrome), vascular anomalies
Gastrointestinal   Dyspepsia, gastroesophageal reflux, nausea, vomiting (sometimes cyclical), diarrhea and/or constipation (often 
alternating), gastroparesis, angioedema, dysphagia (usually proximal), bloating/gas (usually post-prandial, 
often acute/subacute, sometimes to the appearance of full pregnancy), migratory abdominal pain from luminal 
or solid organ inflammation or distention, malabsorption; cholecystectomy is common, though often yielding 
normal pathology; ascites is rare
Genitourinary   Migratory luminal and solid organ inflammation (“urinary tract infection,” often culture-negative, is commonly 
misdiagnosed instead of interstitial cystitis), chronic kidney disease, endometriosis, chronic back/flank/
abdominal pain, infertility, decreased libido, vulvodynia, vaginitis (often misdiagnosed as infectious), painful 
and/or irregular dysmenorrhea, menorrhagia; miscarriages are common and occasionally signal an anti-
phospholipid antibody syndrome possibly rooted in MCAS
Musculoskeletal/
connective tissue
  Migratory bone/joint/muscle pain (co-diagnosis of fibromyalgia is common), joint laxity/hypermobility 
[co-diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) is common], osteopenia/osteoporosis 
(osteosclerosis is seen but is rare), and other tissue growth/development anomalies (i.e. dystrophisms, usually 
benign) such as cysts, fibrosis, vascular anomalies such as hemorrhoids, aneurysms, and arteriovenous 
malformations, occasionally even liquid or solid malignancies
Neurologic   Headache, sensory neuropathies (most commonly episode/migratory paresthesias in the distal extremities), 
episodic weakness (though proven motor neuropathy is rare), dysautonomias, seizure disorders, 
“pseudoseizures” (likely dysautonomic events), cognitive dysfunction (most commonly memory, concentration, 
and/or word-finding difficulties), dyssomnias (insomnia, frequent waking, hypersomnolence, non-restorative 
sleep, restless legs; less commonly or rarely: sleep apnea, sleepwalking, sleep talking, sleep paralysis, night 
terrors)
Psychiatric   Mood disturbances (e.g. depression, anger/irritability, mood lability), anxiety disorders (anxiety, panic, 
obsession-compulsion), attention deficit/hyperactivity; frank psychosis is rare
Endocrinologic/
metabolic
  Abnormal electrolytes and liver function tests, hypo- or hyperthyroidism (often just sheer (but modest) lability 
of thyroid function), dyslipidemia, impaired glucose control (hyperglycemia, hypoglycemia, glycemic lability), 
hypo- or hyper-ferritinemia; nutritional deficiencies are often suspected but are relatively rare, more commonly 




  Polycythemia or anemia [typically just mild, most commonly normocytic but sometimes macrocytic or microcytic; 
other causes (e.g. iron deficiency), whether consequent to MCAS or not, must be ruled out and addressed; 
note that “normal” erythropoietic parameters (a relative polycythemia?) may seem odd given the extent of 
chronic multisystem inflammation], leukocytosis or leukopenia (typically mild), monocytosis or eosinophilia 
or basophilia (typically modest, occasionally moderate or even robust), thrombocytosis or thrombocytopenia 
(typically mild), arterial and/or venous thromboembolic disease, otherwise inexplicable “easy” bruising/
bleeding (co-diagnosis of mild type 1 von Willebrand disease is common, too); there usually is no histologic or 
molecular evidence of MC aberrancy in the marrow in MCAS, but sometimes a modest hypocellularity or mild 
myeloproliferative or myelodysplastic appearance is seen, insufficient for diagnosis of a myeloproliferative 
neoplasm or myelodysplastic syndrome, and genetic and flow cytometric analyses almost always are normal
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receptor, dominantly expressed by T-cells) and/or CD2 
(ordinarily a surface adhesion molecule restricted to T/
NK-lymphocytes)], and (2) far more common patients 
with “idiopathic” MCAS, which preliminary research 
[15–17] strongly suggests is almost always driven by one 
(largely MC-restricted, largely somatic) mutational profile 
or another among a very large menagerie of such profiles 
in KIT and other MC regulatory elements. Unfortunately, 
such somatic mutational profiling in MCs is not presently 
available in clinical laboratories, relegating such patients 
to an “idiopathic” diagnosis. We acknowledge a diagnos-
tic category of “secondary MCAS,” but its diagnosis and 
treatment pales in importance compared to “primary” 
and “idiopathic” MCAS given that in secondary MCAS, it is 
expected that treatment of the underlying disorder, which 
presumably is driving normal activation of the patient’s 
exclusively normal MCs, will result in improvement of the 
MCAS. As such, all mentions of “MCAS” subsequently 
in this paper should be taken to refer to primary and idi-
opathic MCAS. Also, the behavior of cutaneous mastocy-
tosis (CM, grossly limited to cutaneous presentation of 
mastocytosis, though recent research now suggests all 
cases of CM, at least in adults, can be found to have cir-
culating, thus systemic, clonal mast cells) [18] shares far 
more of the behaviors of systemic mastocytosis (SM) than 
of MCAS. Therefore, all subsequent mentions of “SM” 
should be taken to refer to SM and CM.
Methods
We first identified the full sets of literature revealed, as of 
October 27, 2019, by searches for “mast cell activation syn-
drome” at both pubmed.gov (138 total articles) and scholar.
google.com (1410 total articles). We identified publications 
offering new or modified schemes for diagnosing the full 
range of MCAS (excluding those addressing only subsets, 
such as monoclonal MCAS). We found nine such publica-
tions [7–9, 19–24], reviewed them, and found each to fall into 
one of two principal schools of thought as defined by their 
original papers [8, 9]. Our analysis proceeded from these 
groupings, with attempts to assess each “school” for (1) 
validity of diagnostic criteria, (2) diagnostic accuracy, and 
(3) practicality. We also searched similarly for “hereditary 
alpha-tryptasemia” (HAT) and “TPSAB1” (1 article for the 
former term and 150 for the latter term at pubmed.gov, 44 for 
the former and 847 for the latter at scholar.google.com) and 
read the entirety of the principal papers to date [25, 26], as 
well as a few selected other papers from these searches [27–
30], to garner insights into the relationships between MCAS 
and the newly recognized, seemingly similar entity of HAT.
Results
Valent et al. proposal for diagnostic criteria 
for MCAS
The Valent et al., or “consensus,” proposal [9] (re-termed 
here as “consensus-1”) and its recent update [22] are 
described in detail in the first entry in Supplementary 
Table 1. (Readers are encouraged to review Supplementary 
Table 1 in detail at this point in order to better understand 
the following discussion regarding the various diagnostic 
criteria proposals.) The “20% + 2” formula for interpret-
ing rises in tryptase, newly introduced in this proposal, 
as the sole acceptable (even “gold standard”) laboratory 
parameter for diagnosing MCAS bears special attention 
(again, see Supplementary Table 1).
We remain open to the possibility that “20% + 2” 
(or any other formula for interpreting tryptase levels or 
changes in levels) might be applicable to the broad MCAS 
population, discriminating that population from the even 
broader population of those without MCAS. However, we 
cannot see, given the slew of issues about this formula, 
that “20% + 2” can be reasonably viewed yet as a valid 
(let alone sole, or “gold standard”) laboratory diagnostic 
criterion for MCAS (except possibly in the two uncommon 
anaphylactic settings referenced in Supplementary Table 
1). It remains unclear to what extent “consensus-1” is (or 
System   Potential manifestations of MCAD
Immunologic   Hypersensitivity reactions, increased risk for malignancy and autoimmunity, impaired healing, increased 
susceptibility to infection, increased or decreased levels of immunoglobulin of any isotype; monoclonal 
gammopathy of undetermined significance (MGUS) is occasionally seen
Few patients display all of these symptoms; most display subsets, and the heterogeneity of full clinical profiles among MCAD patients 
is extreme. Most symptoms are chronic and low-grade; some are persistent, but many are either episodic or waxing/waning. More 
comprehensive lists and discussions, including less common symptoms, are available (e.g. [13–14]).
Table 1 (continued)
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warrants becoming) a consensus beyond that sensed by 
the authors on the papers advocating these criteria.
Molderings et al. proposal for diagnostic 
criteria for MCAS
The original and updated Molderings et al. proposals [8, 
20, 21] are described in the second entry in Supplemen-
tary Table 1. We propose that the Molderings et al. 2017 
criteria [21] now be known as the “consensus-2” criteria 
(to distinguish from “consensus-1”). “Consensus-2” is a 
consensus, too: another set of criteria regarded by the 
sizable contingent of investigators authoring this paper 
as valid for diagnosing the extraordinarily complex and 
variable disease that is MCAS, compared to a somewhat 
different perspective held by other investigators who 
first decided to label their perspective on the disease as a 
“consensus.” We further note there has not yet been even 
a single study comparing the validity of any one proposal 
for MCAS diagnostic criteria against any other such pro-
posal. Not that sheer popularity is a good tool for estab-
lishing scientific truth, but the consensus-2 proposal in 
this paper is now endorsed by a much larger group of 
investigators (from almost all medical specialties) than 
in the prior Molderings et al. proposals – a group which 
now collectively has seen well more than 10,000 patients 
who have behaved clinically and therapeutically in a 
fashion more consistent with chronic aberrant MCA than 
any other known pathologic process. This consensus-2 
proposal simply presents a different, somewhat “larger” 
perspective, born of at least equally extensive clinical 
experience as held by the consensus-1 authors, regard-
ing the natural behavior of a large set of diseases which 
appear to have a common root in chronic aberrant MC 
activation, with only modestly increased MC accumula-
tion not rising to the gross levels, and with abnormal MC 
histomorphology, seen in SM.
It is not yet known which proportions of the popu-
lations afflicted by any of the many comorbidities often 
seen with MCAS [e.g. myalgic encephalitis/chronic fatigue 
syndrome (ME/CFS), fibromyalgia, irritable bowel syn-
drome (IBS), postural orthostatic tachycardia syndrome 
(POTS), small fiber neuropathy (SFN), hypermobile Ehlers 
Danlos Syndrome (hEDS), and many others] [12] actually 
have MCAS, and whether each of those comorbidities is 
truly caused by MCAS or is merely associated with MCAS. 
Generally, those favoring the consensus-2 criteria have 
observed non-trivial overlaps among the populations with 
these diseases (e.g. [31–35]), hinting at commonalities in 
these diseases’ mechanistic roots, and those favoring the 
consensus-1 criteria have published contrary assertions 
(e.g. [23, 24, 36]).
Other proposals for diagnostic criteria for 
MCAS
Three additional proposals [19, 23, 24] – all modest variants 
of the “consensus-1” criteria – have emerged, as detailed 
in the third through fifth entries in  Supplementary Table 1.
Discussion
MCA disorders (largely as allergic-type diseases and more 
complex presentations now termed “MCAS”) are preva-
lent, judging merely by the known 10–50% global preva-
lence of allergy (e.g. [37–43]). This figure unsurprisingly 
is congruent with not only some of the higher estimates 
of prevalence for MCAS [11, 44, 45] but also (given that 
chronic multisystem inflammation is, more than any 
other clinical feature, the sine qua non of MCAS) estimates 
for prevalence of the spectrum of chronic inflammatory 
diseases [43, 46, 47]. Mastocytosis, on the other hand, is 
a rare disease [20]. As such, the global impact of accu-
racy in diagnosing MCAS likely is much greater than in 
 diagnosing SM.
For any disease, misdiagnosis (whether underdiag-
nosis or overdiagnosis) is problematic for patients and 
society, typically delaying (or even permanently prevent-
ing) patients from accessing effective treatment and, thus, 
perpetuating suffering and even disability and the accom-
panying loss of productivity. Many studies (e.g. [48–52]) 
have shown misdiagnosis is common, even for common 
disorders. MCAD, too, is challenging to learn to recog-
nize and challenging to diagnose [12, 34, 53]. Given the 
extraordinary array of MC mediators and their extraordi-
nary arrays of direct and indirect, local and remote, acute 
and delayed and chronic effects in cells/tissues/organs/
systems throughout the body, it seems likely that MCAD 
would be an area especially prone to misdiagnosis, largely 
in the form of patients misdiagnosed with diseases in 
truth consequential to MCAD as opposed to other diseases 
(e.g. carcinoid) being misdiagnosed as MCAD. This latter 
risk likely can be substantially tempered by the diagnos-
tician’s diligence in adherence to the criteria, including 
absence of processes/diseases other than chronic aberrant 
MCA, which better account for the full range and duration 
of the patient’s problems. Differential diagnoses for MCAS 
have been considered in the literature (e.g. [20, 34]); a few 
such considerations include diabetes mellitus, porphyria, 
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sarcoidosis, thyroid disorders, Fabry disease, Helicobac-
ter pylori gastritis, infectious and inflammatory bowel 
and skin and genitourinary tract diseases, celiac disease, 
lactose/sucrose/fructose intolerance, amyloidosis, intesti-
nal adhesions/volvulus/obstruction, hepatitis, cholecys-
titis, median arcuate ligament syndrome, neuroendocrine 
cancers (carcinoid, pheochromocytoma, etc.), pancreatic 
endocrine tumors, food/environmental allergy, asthma, 
allergic rhinitis, eosinophilic esophagitis/enteritis, other 
hypereosinophilic and hyper-IgE syndromes, immuno-
deficiencies, autoinflammatory syndromes, hereditary 
angioedema, vasculitis, hypermobility syndromes, lym-
phoma, myeloproliferative neoplasms, autism, anxiety/
panic, depression, psychosomatism, conversion disorder, 
and Munchausen’s syndrome. As merely one example of 
the intersection of MC activation with other diseases, MCs 
closely interact with neurons [54, 55] and can be activated 
and increased in numbers in gastrointestinal neuropathic 
disease [56]. Full thickness luminal gastrointestinal tract 
biopsy may be important in the diagnosis in carefully 
selected cases where gastrointestinal tract dysmotility is 
evident and MC disease is suspected [57], but the utility 
of this approach in patients with luminal gastrointestinal 
tract dysmotility overall remains unclear and needs more 
research, especially given our own experience that more 
commonly obtained, safer (especially given the associa-
tion of MCAS with diseases of connective tissue frailty), 
non-full-thickness (i.e. mucosal and submucosal) biop-
sies usually are sufficient for assisting in diagnosis of 
MCAS (with or without gastrointestinal dysmotility) by 
the consensus-2 criteria. All in all, careful consideration 
by the diagnostician of the full spectrum of the patient’s 
problems is needed, as well as recognition that some accu-
rate diagnoses (e.g. chronic idiopathic urticaria), though 
perhaps subsumed by a more encompassing diagnosis 
of MCAS, may, nevertheless, be effectively addressed by 
standard treatment for the more limited diagnosis.
The extent of unnecessary suffering from underdiag-
nosis of MCAS is amplified by present estimates of progno-
sis in MCAS of a normal lifespan in most. Delay in access 
to effective treatment for MCAS may stretch decades and 
likely was present lifelong before MCAS became recog-
nized. (Indeed, an MCAS patient’s history often will date 
back to a childhood of excessive “colic,” “allergies,” “food 
intolerances,” dysmenorrhea/menorrhagia soon after 
menarche, and other inflammatory or allergic-type prob-
lems either incorrectly diagnosed as normal or dismissed 
as of unknown cause and insignificant.) The adverse 
consequences on both personal and societal scales seem 
incalculable. In our collective experience, most patients 
diagnosed with MCAS using the consensus-2 criteria 
experience meaningful improvement – sometimes quite 
astounding improvement – with MC-directed therapies no 
matter the years to decades they have suffered with pre-
viously unexplained multisystem issues not infrequently 
leading to partial or full disability.
Despite important agreements among the diagnostic 
proposals (see Table 2), comparison reveals significant 
differences. The “consensus-1” proposal – based on clini-
cal observations of a highly experienced but relatively 
small group of investigators focused principally in SM 
(a disease significantly different from MCAS in key sero-
logic, histomorphologic, and genetic factors) – considers 
only severe, recurrent flares of a small number of spe-
cific symptoms as meaningful in determining a diagno-
sis of MCAS; the modified AAAAI proposal even requires 
recurrent anaphylaxis. The “consensus-2” proposal – also 
based on clinical observations of a highly experienced, 
large group of clinicians and investigators increasingly 
focused on MCAS – considers a far wider range of symp-
toms (all consistent with known effects of the established 
great repertoire of MC mediators) which often respond to 
MC-targeted therapies, thus making it seem reasonable 
to consider, in appropriate clinical context (i.e. not with 
any one symptom observed in isolation), diagnostic utility 
in this larger range of symptoms. Carefully designed and 
executed research will be required to identify whether 
either proposal is considering the most correct range of 
symptoms or should regard as diagnostically useful a 
smaller – or a greater – range of symptoms.
Table 2: Broadly accepted characteristics defining the mast cell activation syndrome (MCAS) population.
1.  An MCAS patient must have symptoms consistent with chronic MCA, which is aberrant (i.e. abnormal, whether constitutive/baseline and/
or reactive to some identifiable trigger; note most MCAS patients have both constitutive and reactive MCA, even if either form is just to a 
modest degree at a given point), and, in many patients, accompanied by periodic flares (a.k.a. “spells,” “episodes,” and such) of certain 
subsets of their symptoms
2. An MCAS patient must have signs/symptoms of aberrant MCA in multiple (i.e. at least two) organ systems
3.  An MCAS patient must (with reasonable confidence) not have some other disease accounting better than MCA for the full range and 
duration of the observed symptoms/signs
The characteristics listed here are a synthesis of the published proposals for diagnostic criteria for MCAS [7–9, 20–22, 24].
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The proposals differ, too, in the laboratory criteria they 
consider. The consensus-1 proposal asserts (though seem-
ingly without evidence) that a rise in serum total tryptase 
by “20% + 2” ng/mL is a preferred marker of MCA, though 
if a patient cannot be shown to have “20% + 2,” then eleva-
tions in a few other relatively MC-specific mediators can 
be considered diagnostic. These other mediators include 
prostaglandin D2 (PGD2) or its immediate 11-β-PGF2α 
metabolite, and urinary histamine metabolites [generally 
taken to be just N-methylhistamine (N-MH) as N-methyl-
imidazolacetic acid (MIMA) is no longer readily testable 
at clinical laboratories, at least in the United States]. The 
“consensus-2” proposal states that levels of a slightly wider 
range of mediators relatively specific to the MC [tryptase, 
chromogranin A (CgA), heparin, PGD2, histamine, N-MH, 
11-β-PGF2α, and leukotriene E4 (LTE4)], which rise above 
their normal ranges can be taken as diagnostic laboratory 
evidence of MCAS in the proper clinical context of other-
wise unexplained chronic multisystem issues of generally 
inflammatory ± allergic ± dystrophic themes. Like tryptase, 
heparin is highly (though not perfectly) specific to the MC 
[58], and some published research now suggests an ele-
vated plasma heparin level likely is the single most sensi-
tive marker of MCA, with approximately 80% of patients 
clinically demonstrating symptoms consistent with MCA 
showing increased levels of plasma heparin when meas-
ured using a sufficiently sensitive assay [58]. In clinical 
practice, the biological and logistical challenges of meas-
uring heparin need to be addressed to ensure accurate 
results. CgA is a known product of the MC [59, 60], and if the 
few other diseases known to produce elevated chromogra-
nin A (heart or kidney or liver failure, proton pump inhibi-
tor use, neuroendocrine cancer, chronic atrophic gastritis) 
can be reasonably confidently excluded in a patient with 
symptoms consistent with chronic aberrant MC mediator 
release, it seems reasonable to consider that an elevated 
serum CgA level likely is stemming directly from the aber-
rantly activated MCs. PGD2 is produced by several types of 
cells [61–69], but the MC produces roughly a thousandfold 
more PGD2 than any of the other types of cells [70, 71], so 
when an elevated PGD2 level – in serum and/or urine – is 
seen in a patient with symptoms consistent with MCA, it 
seems most likely that the elevated PGD2 level is domi-
nantly sourced from dysfunctional MCs. 11-β-PGF2α is the 
principal immediate metabolic product of both PGD2 and 
PGE2 [72–74]. Although the MC is known to bear receptors 
for PGE2 [75–77], it appears to produce only low levels of 
PGE2 [78] and does not appear to increase PGE2 produc-
tion in inflammatory conditions [79], so it is possible that 
elevated levels of 11-β-PGF2α may be rooted in activation of 
cells other than MCs, which are producing elevated levels 
of PGE2 (e.g. endothelial cells [79]). Yet, when an elevated 
level of 11-β-PGF2α is seen in the context of symptoms more 
consistent with MCA than other processes, it seems rea-
sonable to consider that the elevated 11-β-PGF2α level is 
sourced primarily from dysfunctional MCs. More recently, 
it has been suggested that 17-β-PGD2α is the best of the PGD2 
metabolites to measure in seeking evidence of MCA, but 
this test is not yet routinely available at any commercial 
clinical laboratories [80]. Histamine is produced by the MC 
and a range of other cells [81], and it is acknowledged that 
histamine, like tryptase and CgA, can be elevated in a range 
of diseases and pathologic states. Yet, again, when hista-
mine is found elevated (in whole blood, serum, plasma, 
or urine) in the context of symptoms more consistent 
with chronic aberrant MC mediator release than any other 
known pathologic process, it seems reasonable to consider 
that the elevated histamine level is sourced primarily from 
dysfunctional MCs. Via histidine N-methyltransferase, 
N-MH is the principal immediate metabolic breakdown 
product of histamine filtered by the kidney into the urine 
[82, 83], but given the range of possible cellular (and even 
dietary) sources of histamine, it would seem no more fea-
sible to pinpoint the source of an elevated N-MH on MCA 
than on any other process producing an elevated level of 
histamine. Thus, we again note the importance of context 
in interpreting relevant findings in an MCAS patient and 
assembling an overall clinical picture more supportive of 
this diagnosis and less supportive of any other.
With the possible exceptions of heparin and tryptase, 
it simply is not possible at present to identify the precise 
range of cellular sources for each of the mediators pres-
ently proposed for testing in one MCAS diagnostic proposal 
or another. Therefore, it would seem to be unnecessar-
ily restrictive to exclude consideration of, say, histamine 
testing or CgA testing simply because one can never be per-
fectly sure that such mediators are dominantly MC sourced.
Identification of other mast cell mediators which 
might have utility in diagnosing MCAS is an area of active 
investigation (e.g. [84, 85]), but questions remain regard-
ing whether such mediators (e.g. interleukin-1β [84] and 
interleukin-6, interleukin-31, tumor necrosis factor, or 
vascular endothelial growth factor [85]) are “sufficiently” 
specific to the MC to warrant their having significance vis-
à-vis a diagnosis as important as MCAS. It is possible that 
some MC mediators, while being of insufficient specific-
ity for diagnostic purposes, may nevertheless eventually 
demonstrate utility for therapeutic efficacy monitoring 
purposes in at least some MCAS patients, i.e. in at least 
some variants of MCAS.
As it is presently worded (in both the original pro-
posal in 2012 and the “update” in 2019), the “consensus-1” 
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proposal requires that MCAS patients demonstrate at least 
partial response to antihistamines and/or cromolyn as an 
essential diagnostic criterion, while the “consensus-2” 
proposal permits demonstration of such a response to be 
considered a minor diagnostic criterion. It is understood 
that both diagnosis and therapy are imprecise arts, and 
it often is the case in practice that therapeutic response 
(or lack thereof) leads to alterations in diagnostic think-
ing. However, we are unaware of other diseases for which 
diagnostic criteria require demonstration of therapeutic 
response. Generally, it is acknowledged that diagnosis 
is what should principally inform therapeutic decision 
making. It is concerning, too, that treatment response be 
required to establish diagnosis of a disease of complex-
ity so great it seems virtually certain that at least some 
patients might not respond to any of the therapies pres-
ently known to have utility in some patients. Accurate 
diagnosis would still be important in such patients vis-
à-vis forthcoming treatments. It also is concerning that 
specification of such a limited set of treatment options in 
a proposal for diagnostic criteria might suggest to most 
practitioners that if the patient does not respond to any 
of these few treatments, then it must not be possible for 
the patient to have the disease – a precept which is highly 
unlikely given, again, the extraordinary complexity and 
heterogeneity of the disease (implying, and as has actu-
ally been found, a large array of treatments found helpful 
in various patients). Thus, in an effort to avoid underdi-
agnosis – especially of a disease which, once diagnosed, 
usually is effectively treatable in one fashion or another 
– listing of specific treatments in a set of diagnostic cri-
teria would seem to be counterproductive. In our experi-
ence, the range of treatments effective in patients meeting 
“consensus-2” criteria is far broader than those listed in 
the “consensus-1” criteria.
Although none of the published proposals for diag-
nostic criteria for MCAS comprehensively specifies the 
types or numbers of mast cell stabilizers or mediator 
antagonists, doses, or durations which should be tried to 
establish the therapeutic response considered by some 
proposals as a required or optional diagnostic criterion, 
treatments commonly tried early, at standard doses as used 
in most other applications, include H1 and H2 histamine 
receptor antagonists, leukotriene receptor antagonists, 
cromolyn, and, in patients without prior adverse reactions 
to such, non-steroidal anti-inflammatory drugs. Treat-
ment response criteria (e.g. “partial response,” “complete 
response”) have not yet been defined by any group, and 
this is likely to be a challenging endeavor in itself given 
that the complex (patho)physiology of the disease some-
times results in finding unexpected benefits rather than 
expected benefits. Clinical judgment, taking into account 
observed symptoms and findings and known mast cell 
(patho)physiology, is appropriate in treating MCAS, often 
starting inexpensively. Setting aside the observation that 
rapid demonstration of intolerance of a drug being tried 
for MCAS should immediately invite cessation of the drug 
and consideration of potential excipient-driven reactivi-
ties, in our estimation most drugs tried for MCAS which do 
not demonstrate clear benefit by 2–4 weeks after having 
reached a “reasonably potent” dose should be abandoned 
out of futility. A comprehensive review of the pharmaco-
therapy of MCAS has been published [86].
The theme we are constantly reminded in our con-
siderations of various proposals for diagnostic criteria 
for MCAS is that MCAS is a very complex disease from the 
clinical to the molecular level (including mediators, genes, 
and epigenes) [11, 15–17, 80]. As such, a clinical diagnosis 
of MCAS – i.e. a case of MCAS worthy of treatment – vir-
tually certainly will never rest on meeting merely a single 
diagnostic criterion (e.g. a single laboratory test meeting 
a specific threshold). As is the case with most syndromes, 
the diagnosis of MCAS will continue for many years to 
come to rest on the demonstration of a specific constel-
lation of findings, i.e. the presence of each finding in the 
context of other findings also congruent with the diagnosis. 
In such a scheme, where the presence of multiple crite-
ria creates a natural system of “checks and balances,” the 
likelihood of misdiagnosis based on inappropriate inter-
pretation of any one observation in the patient dramati-
cally diminishes.
How does familial hypertryptasemia fit into 
the mast cell disease construct?
First described merely a few years ago by investigators 
in Spain [25] and at the U.S. National Institutes of Health 
[26], familial hypertryptasemia, also termed hereditary 
alpha-tryptasemia (HAT), has been defined as a chroni-
cally elevated serum tryptase level coincident with the 
finding of redundant copies of the alpha tryptase gene 
TPSAB1 (though even that definition has been challenged 
by the finding that ~8% of the patients with redundant 
TPSAB1 have no elevations in tryptase). HAT appears to be 
prevalent (approximately 4–6% of the population), and 
the described clinical spectrum of HAT seems to fit well 
within that of MCAS. Thus far, no differences have been 
identified between prognosis or recommended manage-
ment for HAT patients vs. MCAS patients, and the finding 
of HAT patients with normal tryptase levels raises other 
questions. To what extent (if any) are the elevations in 
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tryptase seen in most HAT patients, and the redundant 
TPSAB1 genes seen in all HAT patients (by definition), 
actually causing the chronic aberrant MC release of a wide 
range of mediators suggested by the wide range of symp-
toms in these patients (as in most MCAS patients)? Or, is 
TPSAB1 redundancy merely associated with other muta-
tions more responsible for driving the aberrant constitu-
tive and reactive MC mediator release in HAT patients? 
Furthermore, although the principal function of tryptase 
is not yet known [87, 88], the range of what is known about 
tryptase’s biological functions makes it unlikely that the 
modest elevation in tryptase seen in most HAT patients 
would be the driver of any of their symptoms, let alone 
most or all of their symptoms. As such, it seems likely that 
the redundant TPSAB1 genes and the modestly elevated 
tryptase levels in HAT patients are associated with, but 
not causative of, the MCAS-like symptoms catalogued in 
most HAT patients. At present, then, HAT appears to us 
to be merely one of the myriad of subsets of MCAS (such 
as some of the rare inborn autoinflammatory syndromes 
are increasingly appearing to also be). Therefore, given 
that there are no prognostic or therapeutic differences 
yet identified between HAT and MCAS, it would appear 
that the only utility in TPSAB1 testing is in investigative 
settings and in pursuing a diagnosis of MCAS per consen-
sus-2 criteria in patients with a persistent, mild tryptase 
elevation (e.g. ≤20 ng/mL), as such a finding (inferring 
the elevated tryptase level might be stemming from the 
TPSAB1 redundancy and that such a redundancy might 
actually be merely an incidental finding with no clinical 
effects) might then incline the diagnostician to search for 
additional (non-tryptase-based) laboratory evidence of 
MCA before making a definitive diagnosis.
Why the rush?
This question is imperative in judging at this time the 
validity/utility of the various proposals for MCAS diagnos-
tic criteria. At this very early point in our understanding 
of an obviously extremely complex disease (as one would 
expect of a disease rooted in a cell intrinsic to the sur-
vival of all eukaryotes for >500  million years now) [89], 
it is unclear why only one proposal for diagnostic crite-
ria should be considered acceptable. There likely will be 
many revelations to come in the basic and clinical sci-
ences of MCA, which will significantly affect valid MCAS 
diagnostic criteria. Despite the problems readily apparent 
with the consensus-1 proposal for diagnosing MCAS, it 
need not be dismissed or replaced at this time. Instead, 
there presently seems to be ample room for using both the 
consensus-1 and consensus-2 proposals (and likely others, 
too) for diagnosing MCAS (analogous to how evolv-
ing, steadily more complicated proposals for diagnostic 
schema for mastocytosis, sometimes with “provisional” 
declarations, frequently emerge), especially as it seems 
increasingly likely that the consensus-1 criteria simply 
diagnose a severe but fortunately small subset of the 
patients diagnosed by the consensus-2 criteria. We thus 
propose that either the consensus-1 or consensus-2 pro-
posal be accepted for diagnosing any given case of MCAS 
until criteria can be developed using the modern, robust 
methodologies now being employed to create classifica-
tion criteria for similarly complex and heterogeneous 
conditions such as lupus [90]. It has been little more than 
a decade since the first case reports of MCAS were pub-
lished; there have not yet been any large-scale studies of 
any aspects of the disease, though a few small-scale such 
studies are beginning to emerge [12, 33, 91]. As such, we 
fail to see why there must be a rush to pronounce only one 
approach as definitively diagnostic of a disease of such 
complexity/heterogeneity. We acknowledge there would 
be advantages to a single approach (principally, com-
parability of patient populations for research purposes, 
thought it should be noted that mutational studies to date 
(e.g. [15–17]) have shown great mutational heterogene-
ity in all MCAS patient populations so studied thus far, 
thus questioning the very feasibility of studying homo-
geneous MCAS populations). On the other hand, it seems 
likely there would be significant drawbacks (principally, 
underdiagnosis from inappropriately narrow criteria) to 
making premature judgments about diagnostic criteria 
for such a yet poorly understood complex/heterogeneous 
entity. If alternative ways come to be recognized to diag-
nose a disease whose clinical behavior seems more easily 
attributable to chronic MCA than any other recognizable 
process – and especially when such diagnoses clearly lead 
to effective treatments benefiting previously unimprov-
able patients – then why not at least tentatively accept 
multiple diagnostic approaches with open arms and allow 
the time needed to adequately vet the true validity of any 
given diagnostic proposal? The perpetuated suffering, and 
occasionally even mortality, consequent to underdiagno-
sis seems counter to the fundamental goal and guiding 
principle of all forms of medicine.
Drawbacks in practice and in research to two 
different diagnostic proposals
As implied above, the principal drawback in clinical 
practice, and, even more importantly, in research, to the 
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persistence of two proposals for diagnostic criteria for 
MCAS is obvious: the inability to compare populations 
diagnosed by one set of criteria against populations diag-
nosed by the other set of criteria.
It is obvious that incomparability is a substantial 
drawback. In clinical practice, diagnostic assessment 
tools which fit well with one proposal may not fit well with 
other proposals; treatment approaches (individual drugs, 
algorithms, etc.) which work well for MCAS diagnosed by 
one proposal may not work as well for MCAS diagnosed 
by any of the other proposals. In research, incomparabil-
ity obviously limits a study’s applicability to the popula-
tion in general and thus diminishes the overall value of a 
study, certainly not an insignificant consideration in these 
days of substantial clinical trial costs.
Another drawback is clear, too: practitioners may find 
an already complex field rapidly becomes unmanageably 
complex in trying to understand which diagnostic and 
therapeutic approaches will best apply to the individual 
patient. Some practitioners may use unmanageable com-
plexity as a reason not to consider the diagnosis at all.
Of course, to expect simplicity in diagnostic criteria in 
such a complex disease would seem to be folly, and though 
it is less pleasant to deal with complexity than to deal with 
simplicity, MCAS is the complex beast that it is. Though 
it is always desirable to try to reduce complexity, at some 
point complexity cannot be reduced further without incur-
ring unacceptable adverse consequences.
Fortunately, these drawbacks, in fact, do not preclude 
pursuing clinical research in MCAS; they merely compli-
cate the matter, an outcome which seems unavoidable and 
perhaps should be embraced (as an opportunity to better 
understand the many variants of the disease) rather than 
feared or avoided. Friendly competition among proposals 
for diagnostic criteria even sets a stage upon which clini-
cal trials can rigorously compare proposal performance 
– certainly a worthy objective expected to help the field 
progress toward harmonization of proposals, and, in the 
end, improved clarity for patients and practitioners alike.
Suggested steps forward in practice
MCAS likely is prevalent [11]. As such, ignorance or dimin-
ishment of it disserves individual patients as well as 
society at large, raising costs to the health care system 
and diminishing worker productivity. The disease is 
complicated and will become ever more so as its patho-
physiology is increasingly unraveled and as its likely great 
many distinct variants come to be identified. Therefore, 
it seems the greatest human good would come first from 
diagnosis – by any set of peer-reviewed, published criteria 
Table 3: Suggested steps forward in MCAS practice in 2020.
1.  We advocate diagnosing MCAS in routine clinical practice based on either of the two peer-reviewed, published proposals for diagnostic 
criteria for MCAS [i.e. the latest iteration of consensus-1 [22] (or its more neuro-inclusive predecessor [9]) or the latest iteration of 
consensus-2 [21]], thereby giving the patient access to concerted therapeutic efforts which are likely to gain significant improvement 
the patient (and society) will enjoy for decades to come. In other words, although the preference for science-grounded practice by all 
health care professionals is recognized, nevertheless, when prioritization becomes necessary, our authorship – a broad collaboration of 
academicians and community practitioners, generalists and specialists of all sorts, including physicians and a broad array of other health 
care professionals, representing truly global thought in this area across five countries on three continents in both hemispheres – strongly 
recommends that practitioners serve human needs first and science second.
2.  Therapies supported by peer-reviewed published evidence obviously are to be preferred over those without such, and higher grades of 
evidence obviously are to be preferred over lower grades. Also, it almost always is better to pursue truly novel therapies in the context 
of an appropriately designed, approved, and monitored clinical trial. However, again, it is merely a decade since the first case reports 
of MCAS were published, and thus a paucity of published evidence supporting various therapies, and many defects in trial design and 
execution, must be expected for decades to come. These deficiencies should not hinder efforts at applying treatments with reasonable 
risk:benefit ratios as (1) most of the present treatments for MCAS bear little risk at the doses typically effective in MCAS, and (2) again, 
most MCAS patients do manage to eventually identify significantly helpful treatment even in spite of having suffered progressive sickness 
and debility from their illness for decades. There are many reasons to expect it will take a long time before our profession learns how 
to design and conduct MCAS studies well and to make truly reliable conclusions from such research. We may know very little thus far 
about MCAS, but even just the little we do know is turning out to be enough to significantly help most MCAS patients. Thus, it would be a 
shame for our profession if many such patients were to continue suffering for decades, years, or even a month longer than necessary just 
because a perfect, unified set of diagnostic criteria or clearly reliable therapeutic guidance is not yet available.
3.  As awareness of MCAS within the general medical community widens, the pace of research, including the opening of clinical trials, will 
accelerate. As can be said for any disease, advancement of the science usually comes best from rigorous research, so clinicians are 
strongly encouraged to remain abreast of research developments and opportunities (e.g. periodically searching clinicaltrials.gov for 
“mast cell” or “mast cell activation syndrome,” or subscribing to research notification services) and to enroll their MCAS patients in 
clinical trials (whether diagnostic, therapeutic, or even merely studying the natural history) to the extent feasible.
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– and then from attempted treatment with any therapy 
which has been found helpful in at least some population 
of MCAS patients. Such generalities, of course, neither 
excuse MCAS-treating clinicians from being judicious in 
use of diagnostic criteria and in selection of therapies to 
be tried (especially given the extreme costs of some thera-
pies) nor excuse MCAS investigators from pursuing well-
designed and -executed studies to make clear the manners 
in which assorted specific variants of the disease behave, 
both in their natural courses and in response to various 
treatments. Further practice recommendations are noted 
in Table 3.
Suggested steps forward in research
As previously noted, the complexity of MC biology (espe-
cially the large number of mediators produced by the MC 
and each mediator’s typically large menagerie of effects), 
together with the data to date suggesting a menagerie of 
mutations (mostly somatic) is present in the dysfunctional 
MCs in most primary MCAS patients [15–17], inescapably 
creates a very large pool/collection of variants of MCAS. 
Each variant has its own complex pathophysiology, with 
similarities among some cases of MCAS but also many 
differences which seem likely to be among the principal 
Table 4: Suggested steps forward in MCAS research in 2020.
1.  Given the challenges created by the complexity and heterogeneity of MCAS, and though recent trends in the conduct of clinical trials have 
emphasized diversity in the recruiting of subjects, MCAS would seem to be an investigational arena calling for even greater precision in 
eligibility criteria, and restriction in diversity, than have historically been defined. In fact, given the likely significant prevalence of MCAS 
in the general population, together with the extreme heterogeneity of the disease’s behavior at all levels, even the eligibility criteria 
for “healthy control subjects” probably could stand some “tightening” to ensure (to a reasonable, affordable extent) that such subjects 
likely do not harbor MCAS. For example, in a study investigating mast cell densities in luminal gastrointestinal tract biopsies, it would 
be insufficient to use “routine screening colonoscopy” patients as “healthy control subjects” unless careful histories have been taken 
from, and physical examinations conducted on, such subjects by an MCAS-familiar clinician to provide reasonable assurance they likely 
do not have MCAS. Otherwise, the “healthy control” cohort could become sufficiently “contaminated” by subjects with unrecognized 
MCAS as to impair the study’s ability to detect distinctions between healthy people and MCAS patients. Examples abound with significant 
adverse consequences in practice arising from poor clinical trial design leading to false conclusions of differences between “control” and 
“affected” cohorts. The complexity of MCAS would seem to only heighten the risk for such consequences unless similarly heightened care 
is taken with regard to trial design.
2.  Unless it is specifically the heterogeneity of MCAS one is seeking to characterize in a study (e.g. [12]), studies examining “general” 
populations of MCAS patients probably are inadvisable, at least until diagnostic evaluation for MCAS advances to where identification 
of the MC mutational profiles likely driving most cases of the disease are routine and provide some expectation of harmony in clinical 
behavior among the patients recruited for a given study.
3.  It seems more appropriate to design MCAS-related studies focused specifically in cohorts with certain associated co-morbidities 
suspected to be underpinned by one particular variant (or a relatively small collection of variants) of MCAS. Perhaps a good starting 
point would be to develop a small “industry” of pilot studies examining the prevalence of laboratory-proven MCAS (as diagnosed by one 
diagnostic criteria proposal or another, per the preference of an individual study’s investigators) within cohorts of patients with one 
co-morbidity or another [e.g. myalgic encephalitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, irritable bowel syndrome (IBS), 
postural orthostatic tachycardia syndrome (POTS, hyperadrenergic (haPOTS) and otherwise), hypermobile Ehlers-Danlos syndrome 
(hEDS), etc.]. At a minimum, this approach would permit the prevalence of laboratory-proven MCAS (whether primary, secondary, or 
idiopathic) within the cohort with that co-morbidity to be defined, perhaps showing, for at least some of those co-morbidities, a non-
trivial prevalence of MCAS and thus a possible new etiologic consideration for at least certain fractions of the populations with these 
various co-morbidities which have long defied great extents of etiologic investigations.
4.  Whenever possible, such initial comorbidity-specific MCAS-prevalence studies should be accompanied simultaneously by correlative 
science studies in which, similar to prior studies [15–17], MC mutational profiles (and epigenetic profiling, too, if feasible) are sought in 
the studied subjects. Given that the subjects studied in the prior studies were “general MCAS patients,” with great heterogeneity in their 
clinical presentations, it is not surprising that such great heterogeneity was also found in the studied subjects’ MC mutational profiles. 
However, it is possible, perhaps even likely, that studies of the MC mutational profiles in cohorts of MCAS patients sharing similar 
clinical presentations (e.g. a cohort of patients with only hEDS, or at least with hEDS and a very limited range of additional comorbidities) 
might discover recurrent mutational profiles (in genomes and even epigenomes) which might be essential in finally unraveling the full 
pathobiology of hEDS and the many other comorbidities found among the “general MCAS population.”
5.  The design of studies investigating molecular mechanisms for the various clinical (mis)behaviors seen in some MCAS patients should 
take into consideration that not all of the dysfunctional MCs in an MCAS patient are dysfunctional in the same manner or at the same 
time. As such, study design probing local, brief expression of (often quite thermolabile) MC mediators may be more revealing than study 
design probing systemic, sustained mediator expression. Such studies may well first require development of new technologies, including 
molecular radiographic technologies such as whole-body imaging of expression of a potent vasodilator such as PGD2 during a flare of 
presyncopal symptoms in a patient with laboratory-proven haPOTS and MCAS.
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challenges of MCAS to the diagnostician. It can be chal-
lenging to recognize that MCAS should be considered in 
differential diagnosis of a patient’s presenting assortment 
of symptoms and findings when the clinical presentation 
can substantially differ from one patient to the next. The 
disease even can vary substantially in its behavior within 
a given patient from one point in time to another (e.g. 
alternating diarrhea and constipation are common), and 
even from one site to another in the same patient at the 
same point in time (e.g. osteopenia/osteoporosis at some 
bony sites and, simultaneously, osteosclerosis at other 
sites). These multiple dimensions of heterogeneity create 
tremendous problems for rigorous study of the disease. 
Each patient in a study of “general” MCAS patients may 
well be more of an “N of 1” than seen with each patient 
in studies of most other diseases, making it very difficult 
to reach definitive conclusions and quite possibly missing 
important diagnostic and therapeutic signals present only 
in various subsets of the MCAS population. We summarize 
our recommendations for addressing these challenges in 
Table 4. Clearly, the complexity and heterogeneity of MCAS 
and the challenges to research posed by various essential 
elements of MCAS biology/pathobiology such as the brief 
half-lives and thermolability of many of the MC’s media-
tors constitute further reason to expect the road ahead in 
this arena will be difficult and slow and further reason 
for measured consideration of diagnostic and therapeutic 
recommendations rather than rushes to judgment.
Conclusions
Mast cell activation syndrome (MCAS) is a recently rec-
ognized clinical entity increasingly appreciated to be 
the correct root diagnosis (i.e. implying response to cor-
responding therapy) for a large number of patients pre-
viously found to have a large assortment of seemingly 
idiopathic chronic multisystem issues of general themes 
of inflammation ± allergic-type issues ± dystrophisms. 
MCAS is extraordinarily complex and heterogeneous in 
its clinical behavior, and as so much remains to be dis-
covered about the underlying biology and pathobiology of 
the MC, it seems likely that appreciation of the full range 
of clinical (let alone molecular) behavior of the disease 
will continue expanding for decades to come. Given such 
expectations, it seems wise to remain receptive to at least 
some variation in views of the disease’s behavior and of 
appropriate diagnostic and therapeutic management, and 
to welcome new views which, taking advantage of new 
research, may explain more observations than perhaps 
afforded by older views. Risk of overdiagnosis likely can 
be managed relatively well by adhering to peer-reviewed, 
published criteria. All in all, there is space for many years 
to come to accommodate not only both the consensus-1 
and consensus-2 proposals for diagnosing MCAS but also 
other proposals which may emerge. It seems likely that 
far more research will be needed before it may become 
appropriate to make a concerted effort to harmonize dis-
cordant proposals. We recognize the WHO for its insight in 
this matter as manifested by its not considering MCAS in 
its recent revision [92] of its consensus diagnostic criteria 
for mastocytosis, and we caution against premature con-
clusions at other upcoming meetings given the marked 
individual and societal risks from underdiagnosis of what 
likely is a very prevalent disease.
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